Biomarkers identified for Avastin resistance in cancer patients

Avastin, Genentech/Roche's trade name for bevacizumab, is frequently used to treat various cancers because it blocks the growth of new blood vessels. But all too frequently, some patients develop a resistance to Avastin. Circadian Technologies has found what it says are two biomarkers that indicate which colorectal cancer patients might be resistant to Avastin. VEGF-C and VEGF-D appear to play roles in chemotherapy resistance. More studies are planned. Release

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.